Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase 1/2 clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. The company was incorporated in 2010 and is headquartered in Tokushima, Japan.
Frequently asked questions
What sector does Delta-Fly Pharma Inc (4598) operate in?
Delta-Fly Pharma Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Delta-Fly Pharma Inc (4598) current stock price?
As of the latest data, Delta-Fly Pharma Inc stock price is ¥105, with a previous close of ¥105.
What is Delta-Fly Pharma Inc (4598) current market capitalization?
Delta-Fly Pharma Inc market cap is approximately 1.49 billion.
What is Delta-Fly Pharma Inc (4598) Earnings Per Share (EPS)?
The trailing EPS is -¥140.
What is Delta-Fly Pharma Inc (4598) EBITDA?
Delta-Fly Pharma Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -420.01 million.
Does Delta-Fly Pharma Inc (4598) pay dividends?
No. Delta-Fly Pharma Inc does not pay a dividend.
What is Delta-Fly Pharma Inc (4598) beta (volatility) score?
Delta-Fly Pharma Inc has a beta of -0.719, indicating lower volatility than the overall market.
